From GlobeNewswire: 2025-03-03 08:00:00

Annexon, Inc. reports robust Phase 3 data and real-world evidence supporting ANX005 as a potential first targeted therapy for GBS. Pre-BLA meeting targeted for 1H 2025 before BLA submission. ANX007 also making progress as a potential first vision-preserving treatment for Dry AMD with GA, with Phase 3 data expected 2H 2026.

ANX1502, an oral C1s inhibitor, shows promise in a POC trial for Cold Agglutin Disease with dosing in three patients. Expanded dataset to include up to seven patients expected mid-2025. Annexon reported a strong balance sheet with approximately $312 million in cash, cash equivalents, and short-term investments as of December 31, 2024, with anticipated runway into 2H 2026.

The company’s lead program, ANX005, is a monoclonal antibody for Guillain-Barré Syndrome (GBS) showing functional improvements and a differentiated safety profile. ANX007 for Dry AMD with GA has demonstrated significant vision preservation. ANX1502, an oral small molecule, is showing promise in the ongoing POC trial for Cold Agglutin Disease.

Annexon’s financial results for Q4 and full year 2024 show strong performance, with cash, cash equivalents, and short-term investments totaling $312 million as of December 31, 2024. R&D expenses increased due to advancement in priority programs. Net loss was $48.6 million for Q4 2024 and $138.2 million for the full year.

Annexon is developing therapeutics to stop classical complement-driven neurodegeneration for serious neuroinflammatory diseases. Their pipeline includes treatments for autoimmune, neurodegenerative, and ophthalmic diseases. The company’s mission is to deliver game-changing therapies to patients to improve their quality of life.



Read more at GlobeNewswire:: Annexon Reports Fourth Quarter and Year-End 2024 Financial